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undergoing redo CABG from January 1998 through July 2014. The
effect of time on the prevalence of redo CABG cases and prior PCI,
and the preoperative patient’s characteristics on postoperative
early outcomes were analyzed. Patients were divided into two
groups based on the period of performance of redo CABG. Group 1:
January 1998 through December 2004 (n¼114) and group 2 : January
2005 through July 2014 (n¼ 95 ). RedoCABGwasperformedusingon-
pump technique in 159patients (group1:107pts andgroup2:52pts) ,
and off-technique in 50 patients (group 1 :7, group 2: 43 patients).
Results: Prevalence of redo CABG decreased from 4.6% in group 1
to 1.36% in group 2 (P¼ 0.000). Prevalence of PCI to redo CABG was
significantly increased from 10.5% in group 1 to 34.7% in group 2
(p¼ 0.000). ITA usage was more in group 1 than group 2 (71.9% vs
57.4%) (p¼ 0.033 ). The number of patients with advanced age, left
ventricular dysfunction and renal insufficiency had increased in
group 2. In hospital mortality did not change between the groups
(6 pts vs 2 pts : p¼ 0.236 ) but the incidence of post-operative low
cardiac output syndrome requiring IABP support has decreased 4
pts vs 2 pts : p¼ 0.691) in the later part of our study.
Conclusions: Surgical coronary revascularization has evolved
during the past one and half decades with redo CABG uncom-
monly performed in contemporary practice. Despite treating pa-
tients with more complex coronary artery disease and greater
medical co-morbidities, there is a significant reduction in opera-
tive morbidity and mortality.
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Background: The Fontan/Kreutzer operation for patients with a
functional single ventricle has undergone major technical modifi-
cations since its introduction in the early 1970’s. The latter modifi-
cation, the intra/extracardiac fenestrated Fontan procedure,
combines theadvantagesof the extracardiac conduit and the lateral
tunnel and has fewer disadvantages. Advantages of the intra/
extracardiac fenestrated Fontan include less risk of injury to the
crista terminals reducing the risk of atrial arrhythmias and easy
access for fenestration. The ring-supported conduit can be placed
working througha standardatrial incisionparallel to theAVgroove,
avoiding injury to the sinus node, the sinus node artery, and the
crista terminalis. A 4mmfenestration is punched in the short intra-
atrial segment of the conduit and suture attaches the atriotomy
incision to the margins of the conduit. An inverted T incision is
made at the bidirectional Glenn shunt anastomosis extending into
the right and left pulmonary artery as well as the superior vena
cava. The beveled superior end of the conduit is sutured to the
pulmonary arteries and cava using a continuous suture.
Methods and results: We report the anatomic and hemodynamic
outcomes in our first 11 patients undergoing the intra/extrac-
ardiac fenestrated Fontan procedure at our institute. Diagnosis
included double outlet right ventricle with or without other car-
diac anomalies, double inlet left ventricle, tricuspid atresia, and
hypoplastic left heart syndrome. Two patients had heterotaxy
syndrome. Mean age and weight at time of operation was 34.9
months and 12.8 kg, respectively. Mean cardiopulmonary bypass
time was 105 minutes and mean cross-clamp time was 58 mi-
nutes. End ventricular diastolic pressure (EDP) were similar pre-
and post-Fontan procedure, 10.6 mmHg and 10.7 mmHg respec-
tively. Mean atrial pressure was higher post-Fontan (8.1 mmHg
and 10.7 mmHg, respectively.) Mean pulmonary artery pressure
(MPAP) was higher post-Fontan (12.9 mmHg and 14.0 mmHg
respectively). Transpulmonary gradient (TPG) was less post-Fon-
tan procedure (4.8 mm Hg and 3.3 mmHg, respectively.) Chest
tubes were removed at a mean of 6.9 days. No patient had more
than mild AV valve regurgitation. Two patients had junctional
rhythm within the first 2 weeks after surgery, but only 1 had
junctional rhythm later than 2 weeks after surgery.
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Background: CTEPH is sequel of acute pulmonary embolism and
afflicts 1%-4% of the patients who have had a pulmonary embolic
episode. The disease is progressive and carries a dismal prognosis.
Methods: Eleven patients underwent Pulmonary endarterectomy
(PEA) for CTEPH. All patients underwent echocardiogram, right
heart catheterization and CT pulmonary angiography to confirm
the diagnosis and establish surgical candidacy.
Ten patients were in NYHA class III and one patient was NYHA
class II. The mean PA pressures ranged from 35 to 60mm of Hg,
PVR varied from 700 to 1600 dynes/-s-cm5.Five patients had Type I
disease and remaining had Type II disease.
All patients underwent bilateral pulmonary thromboendarter-
ectomy on CPB with two periods of deep hypothermic deep cir-
culatory arrest. All patients were electively ventilated overnight.
Results: There was no perioperative mortality The mean PA
pressures postoperatively varied from 25 to 35 mm of Hg and PVR
was below 500 in all patients. The patients after surgery are in
NYHA class I/II and significant improvement in their walk dis-
tance and Quality of life.
Conclusion: PEA offers good symptomatic relief to patients of
CTEPH and carries low morbidity and mortality in our experience.
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Background: Presence of severe pulmonary arterial hypertension
(PAH) in patients undergoing open valve replacement/repair sur-
gery is a marker of increased morbidity and mortality in the post
operative period. Endothelin antagonists have been shown to be
effective in reducing pulmonary pressures in a variety of cases.
However, their efficacy in secondary PAH is not well studied.
Methods: Patients undergoing valve surgery with pre-operative
severe PAH (peak PA systolic pressures >60 mm Hg) were given
ambrisentan 5mg once a day, starting a week before surgery and
continued post-operatively. Pulmonary Artery pressures and
indices of ventricular function were recorded pre-operatively, at
discharge and at 3rd month follow up and compared to similar
surgical patients not given ambrisentan in a single blinded
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